fludarabine has been researched along with bortezomib in 22 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (36.36) | 29.6817 |
2010's | 11 (50.00) | 24.3611 |
2020's | 3 (13.64) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Andreeff, M; Calvert, LR; Faderl, S; Keating, M; McConkey, DJ; Niemer, I; Pahler, JC; Ruiz, S | 1 |
Byrd, JC; Esseltine, DL; Faderl, S; Flinn, IW; Gribben, J; Keating, MJ; O'Brien, S; Rai, K; Sheng, S | 1 |
Denning, MF; Nickoloff, BJ; Qin, JZ; Sitailo, LA; Xin, H | 1 |
Anderson, KC; Ciccarelli, B; Dammacco, F; Ghobrial, IM; Hatjiharissi, E; Jia, X; Leleu, X; Moreau, AS; Ngo, HT; Patterson, CJ; Roccaro, AM; Russo, D; Sacco, A; Treon, SP; Vacca, A; Xu, L | 1 |
Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
Cheson, BD | 1 |
Bahlis, NJ; Barr, PM; Cooper, BW; Dowlati, A; Fu, P; Gerson, SL; Horvath, N; Koc, ON; Lazarus, HM; Snell, MR | 1 |
Buda, G; Orciuolo, E; Pelosini, M; Petrini, M | 1 |
Feliu, J; García-Muñoz, R; Olavarría, E; Zabalza, A | 1 |
Hanzis, C; Hunter, ZR; Ioakimidis, L; Manning, RJ; Patterson, CJ; Sheehy, P; Treon, SP; Tripsas, C; Turnbull, B | 1 |
Alsina, M; Anasetti, C; Baz, R; Jim, HS; Kim, J; Nishihori, T; Ochoa-Bayona, JL; Pidala, J; Shain, K; Sullivan, D | 1 |
Caballero, D; Caballero-Velázquez, T; Castilla-Llorente, C; Encinas, C; Heras, I; López-Corral, L; Martino, R; Pérez-Simón, JA; Rosiñol, L; Sampol, A; San Miguel, J; Serrano, D | 1 |
Adam, Z; Krejčí, M; Pour, L; Ševčíková, E | 1 |
Advani, RH; Anderson, KC; Barlogie, B; Dimopoulos, MA; García-Sanz, R; Gertz, MA; Ghobrial, IM; Gregory, SA; Kastritis, E; Kimby, E; Kyle, RA; Kyriakou, C; Landgren, O; Leblond, V; Leleu, X; Maloney, D; Merlini, G; Morel, P; Morra, E; Munshi, N; Owen, RG; Rummel, M; Terpos, E; Thomas, SK; Treon, SP | 1 |
Treon, SP | 1 |
Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Chammas, MJ; Cutler, CS; Glotzbecker, B; Ho, VT; Kim, HT; Koreth, J; Lange, PB; Nikiforow, S; Reynolds, CG; Ritz, J; Soiffer, RJ | 1 |
Hogan, JJ; Weiss, BM | 1 |
Jayakumar, I; Patel, S; Raj, R; Ramakrishnan, B; Ramanan, KM; Ravichandran, N; Swaminathan, VV; Uppuluri, R | 1 |
Burningham, Z; Chien, HC; Halwani, AS; Li, CY; Morreall, D; Passey, DG; Patil, V; Rasmussen, KM; Sauer, BC; Yong, CM | 1 |
Cai, QQ; Cao, JN; Feng, JF; Gao, Y; Huang, HQ; Jiang, WQ; Jin, J; Li, ZM; Wang, HQ; Wang, XX; Zhang, HL | 1 |
5 review(s) available for fludarabine and bortezomib
Article | Year |
---|---|
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Novel therapies for peripheral T-cell non-Hodgkin's lymphomas.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lymphoma, T-Cell, Peripheral; Nitrogen Mustard Compounds; Pyrazines; Vidarabine | 2009 |
[Therapy of Waldenström´s macroglobulinaemia in the year 2014].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Immunologic Factors; Immunosuppressive Agents; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2014 |
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consensus Development Conferences as Topic; Disease Progression; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2014 |
Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulins; Immunosuppressive Agents; Kidney Diseases; Lenalidomide; Melphalan; Oligopeptides; Paraproteinemias; Pentostatin; Rituximab; Thalidomide; Vidarabine | 2016 |
5 trial(s) available for fludarabine and bortezomib
Article | Year |
---|---|
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Protease Inhibitors; Pyrazines; Treatment Outcome; Vidarabine | 2006 |
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Nervous System Diseases; Neutropenia; Opportunistic Infections; Pyrazines; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2009 |
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclosporine; Drug Synergism; Female; Graft vs Host Disease; Hematologic Diseases; Humans; Immunosuppressive Agents; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Remission Induction; Reoperation; Salvage Therapy; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2013 |
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Topics: Adult; Bortezomib; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Survival Analysis; Tacrolimus; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2015 |
Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Female; Humans; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Vidarabine | 2021 |
12 other study(ies) available for fludarabine and bortezomib
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Complement Membrane Attack Complex; Complement System Proteins; Cysteine Endopeptidases; Cytochromes c; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Enzyme Activation; Glucocorticoids; Glycoproteins; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Mitochondria; Multienzyme Complexes; Neoplasm Recurrence, Local; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteins; Pyrazines; Tumor Cells, Cultured; Vidarabine; X-Linked Inhibitor of Apoptosis Protein | 2003 |
Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Melanoma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protease Inhibitors; Protein Interaction Mapping; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Ultraviolet Rays; Vidarabine | 2006 |
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Boronic Acids; Bortezomib; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Dexamethasone; Drug Evaluation, Preclinical; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukocytes; Oligonucleotide Array Sequence Analysis; Pyrazines; Resveratrol; Signal Transduction; Stilbenes; TCF Transcription Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2008 |
Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Rituximab; Vidarabine | 2010 |
[Modern times: back to past, back to future].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multiple Myeloma; Pyrazines; Rituximab; Vidarabine | 2012 |
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Disease Progression; Disease-Free Survival; Genetic Predisposition to Disease; Humans; Middle Aged; Pyrazines; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2012 |
Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Remission Induction; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2015 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
FLAG With Bortezomib in Childhood Relapsed/Refractory Leukemia: Remission Induction With Limited Toxicity in the Era of Multidrug-resistant Bacteria.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Child; Child, Preschool; Cytarabine; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Vidarabine | 2021 |
Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Chlorambucil; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Kaplan-Meier Estimate; Piperidines; Prednisone; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Rituximab; Treatment Outcome; Veterans; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2021 |